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Abstract 
 
The application of convolutional neural networks (ConvNets) to harness high-content screening 
images or 2D compound representations is gaining increasing attention in drug discovery. 
However, existing applications often require large data sets for training, or sophisticated 
pretraining schemes for the networks. Here, we show using 33 IC50 data sets from ChEMBL 23 
that the in vitro activity of compounds on cancer cell lines and protein targets can be accurately 
predicted on a continuous scale from their Kekulé structure representations alone by extending 
existing architectures (AlexNet, DenseNet-201, ResNet152 and VGG-19), which were 
pretrained on unrelated image data sets. We show that the predictive power of the generated 
models, which just require standard 2D compound representations as input, is comparable to 
that of Random Forest (RF) models and fully-connected Deep Neural Networks trained on 
circular (Morgan) fingerprints. Notably, including additional fully-connected layers further 
increases the predictive power of the ConvNets by up to 10%. Analysis of the predictions 
generated by RF models and ConvNets shows that by simply averaging the output of the RF 
models and ConvNets we obtain significantly lower errors in prediction for multiple data sets, 
although the effect size is small, than those obtained with either model alone, indicating that the 
features extracted by the convolutional layers of the ConvNets provide complementary 
predictive signal to Morgan fingerprints. Lastly, we show that multi-task ConvNets trained on 
compound images permit to model COX isoform selectivity on a continuous scale with errors in 
prediction comparable to the uncertainty of the data. Overall, in this work we present a set of 
ConvNet architectures for the prediction of compound activity from their Kekulé structure 
representations with state-of-the-art performance, that require no generation of compound 
descriptors or use of sophisticated image processing techniques. The code needed to 
reproduce the results presented in this study and all the data sets are provided at 
https://github.com/isidroc/kekulescope. 
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Introduction 
 
Cultured cancer cell lines are limited disease models in that they do not recapitulate the tumor 
microenvironment nor interactions with the immune system[1–6], fundamental properties of 
cellular organization are altered in culture[7], and their response to anticancer drugs is affected 
by both assay heterogeneity[8] and genomic alterations acquired in vitro[9]. However, cancer 
cell lines still represent versatile models to study fundamental aspects of cancer biology[10, 11], 
and the genomic determinants of drug response[3, 12–14]. Hence, the development of 
computational methods to harness the large amount of in vitro cell line sensitivity data collected 
to date to unravel the underlying molecular mechanisms mediating drug activity and identify 
novel biomarkers for drug response is an area of intense research[14–20]. 
Whereas existing computational tools to model in vitro compound activity mostly rely on 
established algorithms (e.g., Random Forest or Support Vector Machines), the utilization of 
deep learning in drug discovery is gaining momentum, a trend that is only expected to increase 
in the coming years[21]. Deep learning techniques have been already applied in numerous drug 
discovery tasks, including toxicity modelling[22, 23], bioactivity prediction[24–30], and de novo 
drug design[31–34], among others. Most of these studies have utilized feedforward neural 
networks consisting of multiple fully-connected layers trained on one of the many compound 
descriptors developed over the last >30 years in the chemoinformatics field[27, 35]. However, 
the high performance of convolutional neural networks (ConvNets)[36–38], a type of neural 
networks developed for image recognition tasks, in finding complex high-dimensional 
relationships in diverse image data sets is fostering their application in drug discovery[21, 39, 
40]. 
 
ConvNets consist of two sets of layers (Figure 1): (i) the convolutional layers, which extract 
features from the input images, and (ii) the classification/regression layers, which are generally 
fully-connected layers that output one value for each of the tasks being modelled. A major 
advantage of ConvNets is that the extraction of features is performed on a fully automatic and 
data-driven fashion, thus not requiring to engineer feature selection or image preprocessing 
filters beforehand[33, 39, 41, 42]. Today, convolutional neural networks are applied to diverse 
image recognition tasks in healthcare and biomedicine[43–46]. An obvious critical element for 
the application of ConvNets is the availability of images for training, or the ability to formulate 
the modelling task of interest as an image classification problem. An illustrative example of the 
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latter is DeepVariant[47], a recently proposed algorithm that uses images of sequencing read 
pileups as input to detect small indels and single-nucleotide variants, instead of assigning 
probabilities to each of the genotypes supported by the data using statistical modelling, as has 
been the standard approach for years. 
 
In drug discovery, applications of ConvNets include elucidation of the mechanism of action of 
small molecules and their bioactivity profiles from high-content screening images[48–50], and 
modelling in vitro assay endpoints using 2D representations of compound structures, termed 
“compound images”, as input[23, 41, 51–53]. Efforts to model compound activity using 
ConvNets trained on compound images were spearheaded by Goh et al., who developed 
Chemception[51, 54], a ConvNet based on the Inception-ResNet v2 architecture[55]. The 
performance of Chemception was compared to multi-layer perceptron deep neural networks 
trained on circular fingerprints in three tasks: prediction of free energy of solvation (632 
compounds; regression), inhibition of HIV replication (41,193; binary classification), and 
compound toxicity using data from the “Toxicology in the 21st Century” (Tox21) project (8,014; 
multi-task binary classification)[56]. Chemception slightly outperformed the multi-layer 
perceptron networks except for the TOX21 task. In a follow-up study, the same group 
introduced ChemNet[51], a learning strategy that consists of pre-training a ConvNet (e.g., 
Chemception[54]) using a large set of compounds (1.7M) to predict their physicochemial 
properties (e.g., logP, which represents an easy task) in order to learn general features related 
to chemistry from the images. Subsequently, the trained networks were applied to model 
smaller data sets using transfer learning. Although such an approach led to higher performance 
than Chemception, a major disadvantage thereof is that it requires the initial training of the 
network on a large set of compounds, which is computationally demanding. More recently, 
Fernández et al. proposed Toxic Colors, a framework to classify toxic compounds from the 
TOX21 data set using compound images as input[23]. Although these studies have paved the 
way for the application of ConvNets to model the bioactivity of compounds using their images as 
input, a comprehensive analysis of ConvNet architectures with a reduced computational 
footprint to model cancer cell line sensitivity on a continuous scale and comparison against the 
state of the art is still missing. Moreover, whether the combination of models trained on widely-
used compound descriptors (e.g., circular fingerprints) and ConvNets trained using compound 
images leads to increased predictive power remains to be studied. 
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Here, we introduce KekuleScope, a flexible framework for modelling the bioactivity of 
compounds on a continuous scale from their Kekulé structure representation using ConvNets 
pretrained to model unrelated image classification tasks. We demonstrate using 8 cytotoxicity 
data sets and in vitro IC50 data for 25 diverse protein targets extracted from ChEMBL version 23 
(Table 1) that compound images convey enough predictive power to build robust models using 
ConvNets. Instead of using networks pretrained on compound images[51], we show that widely-
used architectures developed for unrelated image classification tasks (AlexNet[57], DenseNet-
201[58], ResNet152[59] and VGG-19[60]) are versatile enough to generate robust predictions 
across a dynamic range of bioactivity values using compound images as input. Moreover, 
comparison with Random Forest models and Deep Neural Networks (DNN) trained on circular 
fingerprints (Morgan fingerprints[61, 62]) reveals that ConvNets trained using compound images 
lead to comparable predictive power on the test set. In addition, combining RF and ConvNet 
predictions into model ensembles often leads to increased model performance, suggesting that 
the features extracted by the convolutional layers of the networks provide complementary 
information to Morgan fingerprints. Therefore, our work presents a novel framework for the 
prediction of compound activity that requires minimal deep learning architecture design, 
processing of chemical structures and no descriptor choice, and that leads to improved 
predictive power over the state of the art in our validation on 8 cancer cell line sensitivity and 25 
in vitro potency data sets. 
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Methods 
 
Data Collection and Curation 
We gathered cytotoxicity IC50 data for 8 cancer cell lines and 25 protein targets from ChEMBL 
database version 23 using the chembl_webresource_client Python module[63–65]. To gather 
high-quality bioactivity data sets, we only kept IC50 values for small molecules that satisfied the 
following stringent filtering criteria[8]: (i) activity unit equal to “nM”, and (ii) activity relationship 
equal to ‘=’. The average pIC50 value was calculated when multiple IC50 values were annotated 
for the same compound-cell line or compound-protein pair. IC50 values were modeled in a 
logarithmic scale (pIC50 = −log10 IC50 [M]). We selected the data sets on a purely data-driven 
fashion, as these are the protein targets with the highest number of IC50 values available (after 
applying the stringent filtering and data curation criteria specified above). As for the cell lines, 
we selected these 8 on the basis of data availability as well, and because they are commonly 
used in preclinical drug discovery. Further information about the data sets is given in Tables 1 
and 2. All data sets used in this study are available at https://github.com/isidroc/kekulescope. 
 
Table 1. Cell line data sets used in this study. 
Cell line Description ChEMBL Cell ID 
Cellosaurus 
ID 
Organism 
of origin 
Number of 
bioactivity 
data points 
A2780 
Ovarian carcinoma 
cells 
CHEMBL3308421 CVCL_0134 
Homo 
sapiens 
2,255 
CCRF-
CEM 
T-cell leukemia CHEMBL3307641 CVCL_0207 
Homo 
sapiens 
3,047 
DU-145 Prostate carcinoma CHEMBL3308034 CVCL_0105 
Homo 
sapiens 
2,512 
HCT-15 
Colon 
adenocarcinoma 
cells 
CHEMBL3307945 CVCL_0292 
Homo 
sapiens 
994 
KB 
Squamous cell 
carcinoma 
CHEMBL3307959 CVCL_0372 
Homo 
sapiens 
2,731 
LoVo 
Colon 
adenocarcinoma 
cells 
CHEMBL3307691 CVCL_0399 
Homo 
sapiens 
1,120 
PC-3 
Prostate carcinoma 
cells 
CHEMBL3307570 CVCL_0035 
Homo 
sapiens 
4,294 
SK-OV-3 
Ovarian carcinoma 
cells 
CHEMBL3307746 CVCL_0532 
Homo 
sapiens 
1,589 
 
Table 2. Protein target data sets used in this study. 
Target preferred name 
Target 
abbreviation 
Uniprot 
ID 
ChEMBL ID 
Number of 
bioactivity 
data points 
Alpha-2a adrenergic 
receptor 
A2a P08913 CHEMBL1867 203 
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Tyrosine-protein kinase 
ABL 
ABL1 P00519 CHEMBL1862 773 
Acetylcholinesterase 
Acetylcholinester
ase 
P22303 CHEMBL220 3,159 
Androgen Receptor Androgen P10275 CHEMBL1871 1,290 
Serine/threonine-protein 
kinase Aurora-A 
Aurora-A O14965 CHEMBL4722 2,125 
Serine/threonine-protein 
kinase B-raf 
B-raf P15056 CHEMBL5145 1,730 
Cannabinoid CB1 
receptor 
Cannabinoid P21554 CHEMBL218 1,116 
Carbonic anhydrase II Carbonic P00918 CHEMBL205 603 
Caspase-3 Caspase P42574 CHEMBL2334 1,606 
Thrombin Coagulation P00734 CHEMBL204 1,700 
Cyclooxygenase-1 COX-1 P23219 CHEMBL221 1,343 
Cyclooxygenase-2 COX-2 P35354 CHEMBL230 2,855 
Dihydrofolate reductase Dihydrofolate P00374 CHEMBL202 584 
Dopamine D2 receptor Dopamine P14416 CHEMBL217 479 
Norepinephrine 
transporter 
Ephrin P23975 CHEMBL222 1,740 
Epidermal growth factor 
receptor erbB1 
erbB1 P00533 CHEMBL203 4,868 
Estrogen receptor alpha Estrogen P03372 CHEMBL206 1,705 
Glucocorticoid receptor Glucocorticoid P04150 CHEMBL2034 1,447 
Glycogen synthase 
kinase-3 beta 
Glycogen P49841 CHEMBL262 1,757 
HERG HERG Q12809 CHEMBL240 5,207 
Tyrosine-protein kinase 
JAK2 
JAK2 O60674 CHEMBL2971 2,655 
Tyrosine-protein kinase 
LCK 
LCK P06239 CHEMBL258 1,352 
Monoamine oxidase A Monoamine P21397 CHEMBL1951 1,379 
Mu opioid receptor Opioid P35372 CHEMBL233 840 
Vanilloid receptor Vanilloid Q8NER1 CHEMBL4794 1,923 
 
Molecular Representation 
We standardized all chemical structures to a common representation scheme using the Python 
module standardizer (https://github.com/flatkinson/standardiser). Entries containing inorganic 
elements were entirely removed from the data sets, and the largest fragment was kept to 
remove counterions and solvents. We note that, although imperfect, removing counterions is a 
standard procedure in the field[66, 67]. In addition, salts are not generally well-handled by 
descriptor calculation software, and hence, filtering them out is generally preferred[68].  
 
Kekulé structure representations for all compounds (i.e., ‘compound images’) in Scalable Vector 
Graphics (SVG) format were generated from the compound structures in SDF format using the 
RDkit function MolsToGridImage and default parameter values. SVG images were then 
converted to Portable Network Graphics (PNG) format using the programme convert (version 
ImageMagick 6.7.8-9 2016-03-31 Q16; http://www.imagemagick.org) and resized to 224 x 224 
pixels using a density (-d argument) of 800. The code needed to reproduce the results 
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presented in this study is provided at https://github.com/isidroc/kekulescope. To represent 
molecules for subsequent model generation based on fingerprints, we computed circular 
Morgan fingerprints[61] for all compounds using RDkit (release version 2013.03.02)[69]. The 
radius was set to 2 and the fingerprint lengths to 128, 256, 512, 1024 and 2048. 
 
Machine Learning 
- Data Splitting  
The data sets were randomly split into a training (70% of the data), validation (15%), and test 
set (15%). For each data set, the training set was used to train the ConvNets, the validation set 
served to monitor their predictive power during the training phase, and the test set served to 
assess their predictive power on unseen data after the ConvNets were trained.  
 
- Convolutional Neural Network Architectures and Training  
ConvNets pretrained on the ImageNet[70] data set were downloaded using the Python library 
Pytorch[71]. The structure of the classification layer(s) in each of the architectures used was 
modified to output a single value, corresponding to compound pIC50 values in this case, by 
removing the softmax transformation of the last fully connected layer (which is used in 
classification tasks to output class scores in the 0-1 range). The Root Mean Squared Error 
(RMSE) value on the validation set was used as the loss function during the training phase of 
the ConvNets, and to compare the predictive power of RF, fully-connected neural networks, and 
ConvNets on the test set. We performed grid search to find the optimal combination of 
parameters for all networks. The parameter values considered are listed in Table 3. 
 
We generated an extended version of each architecture by including five fully-connected layers, 
consisting of 4,096, 1000, 200 and 100 neurons (Figure 1). Thus, for each architecture we 
implemented two regression versions, one containing one fully-connected layer, and a second 
one containing five fully-connected layers (abbreviated from now on as “extended”). The feature 
extraction layers were not modified.  
Table 3. Parameters tuned during the training phase using grid search. The names in parentheses indicate the 
parameter name abbreviation used in the main text and figures. 
Parameter Values evaluated 
Learning rate (Lr) 
{0.1, 0.01, 0.001, 0.005, 0.001, 
0.0001} 
Decay rate {0.1, 0.6} 
Annealing rate step {10, 25} 
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Data augmentation (Augmentation) {Yes: 1, No: 0} 
Batch size (Batch) {4, 16, 32} 
 
In cases where the data sets were augmented, the following transformations were applied (as 
implemented in the Pytorch[71] library): (i) 180° rotation about the vertical axis (function 
transforms.RandomHorizontalFlip); (ii) 180° rotation about the horizontal axis 
(transforms.RandomVerticalFlip); and (iii) random 90° rotation (transforms.RandomRotation). In 
the three cases, each transformation was applied at every epoch during the training phase with 
a 50% chance. Thus, in some cases a set of the images might remain intact depending on this 
sampling step during a given epoch. 
 
We used stochastic Gradient Descent algorithm with Nesterov momentum[72] to train all 
networks, which was set to 0.9 and kept constant during the training phase[72]. The parameters 
for all layers, including the convolutional and regression layers, were optimized during the 
training phase. Networks were allowed to evolve over 600 epochs. The networks were allowed 
to evolve over 600 epochs because we did not observe an increase in predictive power in our 
initial experiments if we trained for more epochs. Given the high computational cost associated 
to training these models we decided that 600 epochs represent and appropriate trade-off 
between computational cost and predictive power (see Figure 2). 
 
To reduce the chance of overfitting, we used (i) early stopping, i.e., the training phase was 
stopped if the validation loss did not decrease after 250 epochs, and (ii) 50% dropout[27, 73] in 
the five fully-connected layers (labelled as “Regression layers” in Figure 1) in the extended 
versions of the architectures considered. The training phase was divided into cycles of 200 
epochs, throughout which the learning rate was annealed and set back to its original value at 
the beginning of the next cycle. The learning rate was decreased by 90 or 40% every 10 or 25 
epochs (decay rates of 0.1 and 0.6, respectively; Table 3). 
 
- Fully-Connected Deep Neural Networks (DNN) 
DNN were trained using the Python library Pytorch[71] as previously described[74]. Briefly, we 
defined three hidden layers, composed of 60, 20, and 10 nodes, respectively, and used 10% 
dropout in the three hidden layers[27, 73]. The RMSE value on the validation set was used as 
the loss function during training. The training data were processed in batches of size equal to 
15% of the number of instances. Rectified linear unit (ReLU) activation [27], and stochastic 
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gradient descent with Nesterov momentum, which was set to 0.9 and kept constant during the 
training phase[72], were used to train all networks. The networks were allowed to evolve over 
2,000 epochs, and early stopping was performed in cases where the validation loss did not 
decrease after 200 consecutive epochs. We used 2,000 epochs because this number was long 
enough to reach convergence of the networks. We note that the computational cost associated 
to training fully-connected networks using Morgan fingerprints is much smaller than the 
computational footprint of image-based models, which permitted us to train longer. We note that 
longer training times for networks using Morgan fingerprints can only result in an advantage for 
these over the image-based ones. The fact that the performance of fully-connected networks 
trained on Morgan fingerprints and networks trained on images is comparable indicates that we 
are not biasing our results in favor of the image-based models. 
 
- Random Forest (RF) 
RF models were generated using the Python library scikit-learn[75] based on Morgan fingerprint 
representations, which were calculated as described above. Default parameter values were 
used except for the number of trees, which was set to 100 because higher values do not 
generally increase model performance when modelling bioactivity data sets[15, 76]. Identical 
data splits were used to train the ConvNets, DNN and the RF models.  
 
Experimental Design  
To compare the predictive power of the ConvNets to model cell line sensitivity in a robust 
statistical manner we designed a balanced fixed-effect full-factorial experiment with 
replications[77]. The following factors were considered:  
(i) Data set: 8 cytotoxicity data sets (Table 1). 
(ii) Model: 8 convolutional network architectures. 
(iii) Batch size (Batch): number of compound images processed in each batch during the 
training phase.  
(iv) Data Augmentation (Augmentation): binary variable indicating whether data 
augmentation was applied during the training phase. 
We implemented the following linear model to study this factorial design: 
 
𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛	1: 
	𝑝𝐼𝐶/0 = 𝐷𝑎𝑡𝑎	𝑠𝑒𝑡5 +	𝑀𝑜𝑑𝑒𝑙: +	𝐵𝑎𝑡𝑐ℎ> +	𝐴𝑢𝑔𝑚𝑒𝑛𝑡𝑎𝑡𝑖𝑜𝑛B + 𝜇0 + 𝜀5,:,>,B,F 
(𝑖	 ∈ {1, … ,𝑁LMNM	OPNO = 8}; 	𝑗	 ∈ {1, … ,𝑁FULPBO = 8}; 	𝑘	 ∈ {1, … ,𝑁WMNXY	O5ZPO = 3};	 
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𝑙	 ∈ \1, … ,𝑁M]^FP_NMN5U_ = 2a; 	𝑚	 ∈ \1,… ,𝑁bPcPN5N5U_O = 10a) 
 
where the factors Data seti, Modelj, Batchk, Augmentationl, are the main effects considered in 
the model. The levels “A2780” (Data set), “AlexNet” (Model), “4” (Batch), and “0” (Augmentation) 
were used as reference factor levels to calculate the intercept term of the linear model, μ0, 
which corresponds to the mean pIC50 value for this combination of factor levels. The coefficients 
(i.e., slopes) for the other combinations of factor levels correspond to the difference between 
their mean pIC50 value and the intercept. The error term, ϵi,j,k,l,m, corresponds to the random error 
of each pIC50 value, defined as ϵ5,:,>,B,F =	𝑝𝐼𝐶/05,:,>,B,F −	mean(𝑝𝐼𝐶/05,:,>,B). These errors are 
assumed to (i) be mutually independent, (ii) have zero expectation value, and (iii) have constant 
variance. 
 
We trained ten models for each combination of factor levels, each time randomly assigning 
different sets of data points to the training, validation and test sets. The normality and 
homoscedasticity assumptions of the linear models were respectively assessed with (i) 
quantile–quantile (Q-Q) plots and (ii) by plotting the fitted values against the residuals[77]. 
Homoscedasticity means that the residuals are equally dispersed across the range of the 
dependent variable used in the linear model. A systematic bias of the residuals would indicate 
that the errors are not random and that they contain predictive information that should be 
included in the model[78, 79].  
 
To compare the performance of (i) the most predictive ConvNet for each data set and 
replication, (ii) RF and (iii) DNN models trained on Morgan fingerprints, and (iv) the Ensemble 
models generated by averaging the predictions of the RF and ConvNet models, we also used a 
linear model with two factors, namely Data set and Model. In this case, we only considered the 
results of the ConvNet architecture leading to the lowest RMSE value on the test set for each 
data set and replication. 
  
𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛	2:	 
𝑝𝐼𝐶/0 = 𝐷𝑎𝑡𝑎	𝑠𝑒𝑡5 +	𝑀𝑜𝑑𝑒𝑙: + (𝐷𝑎𝑡𝑎	𝑠𝑒𝑡 ∗ 𝑀𝑜𝑑𝑒𝑙)5,: + 𝜇0 + 𝜀5,:,> 
(𝑖	 ∈ {1, … ,𝑁LMNM	OPNO = 33}; 	𝑗	 ∈ {1, … ,𝑁FULPBO = 4}) 
 
  
 12 
Results and Discussion 
We initially evaluated the performance of ConvNets to predict the activity of compounds from 
their Kekulé structure representations using 8 cytotoxicity data sets. To this aim, we modelled 
the 8 cytotoxicity data sets using four widely-used architectures, namely AlexNet, DenseNet 
201, ResNet-152, and VGG-19 with batch normalization (VGG-19-bn), and the extended 
versions thereof that we implemented by including four additional fully-connected layers after 
the convolutional layers (see Methods and Figure 1). We obtained high performance on the test 
set for all networks, with mean RMSE values in the 0.65-0.96 pIC50 range (Figure 2). These 
errors in prediction are comparable to the uncertainty of heterogeneous IC50 measurements in 
ChEMBL[8], and to the performance of drug sensitivity prediction models previously reported 
[15, 18, 80]. Notably, high performance was also obtained for data sets containing few hundred 
compounds (e.g., LoVo or HCT-15), suggesting that the framework proposed here is applicable 
to model small data sets.  
In order to study the relative performance of the network architectures in a robust manner, we 
implemented a factorial design that we evaluated using a linear model (Equation 1). The linear 
model displayed an R2 value adjusted for the number of parameters of 0.68 (P < 10−12), thus 
indicating that the variables considered in our factorial design explain a large proportion of the 
variation observed in model performance, and hence, its coefficients provide valuable 
information to study the relative performance of the modelling strategies explored here in a 
statistically sound manner. Analysis of the model coefficients revealed that the performance of 
the extended versions of the architectures constantly led to a decrease in the RMSE values of 
~5-10% (P < 10−12; Figure 2), with ResNet-152, and VGG-19-bn constantly leading to the 
highest predictive models. Together, these results thus suggest that the four additional fully-
connected layers we included in the architectures and the use of dropout regularization help 
palliate overfitting (Figure 2), and hence, increase the generalization capabilities of the 
networks.  
To ensure that the low RMSE values observed are not the consequence of simply predicting the 
mean value of the response variable, we examined the distributions of the residuals for the 
ConvNet and RF models (Figure 3). These complementary analyses are important because, as 
we have previously shown for protein-ligand data sets[81], networks that fail to converge often 
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simply predict the mean value of the dependent variable. Overall, we observed similar patterns 
for both modelling approaches (as shown in Figure 3), with residuals centered around zero and 
generally showing homoscedasticity, i.e., displaying comparable variance across the entire 
bioactivity range. Examination of the residuals is also important when modelling imbalanced 
data sets, which is generally the case for data sets extracted from ChEMBL, because a large 
fraction of instances are annotated with pIC50 values in the low micromolar range (4-5 pIC50 
units), and by simply predicting the mean value of the response variable one might already 
obtain low RMSE values (~1 pIC50 units for these data sets, see yellow bars in Figure 4). In 
such cases, the residuals would be heteroscedastic, displaying increasingly higher variances 
towards the low-nanomolar range (i.e., pIC50 values of 8-9), which however was not the case for 
the models generated here. Together, these results thus indicate that compound images convey 
sufficient chemical information to model compound bioactivities across a wide dynamic range of 
pIC50 values. 
In addition, we performed Y-scrambling experiments using the 8 cytotoxicity data sets to ensure 
that the predictive power obtained by the ConvNets did not arise by chance. With this aim in 
mind, the bioactivity values for the training and validation set instances were shuffled before 
training. We observed R2 values around 0 (P < 0.001) for the observed against the predicted 
values on the test set for all the Y-scrambling experiments we performed. Therefore, these 
results indicate that the features extracted by the convolutional layers capture chemical 
information related to bioactivity, and that the high predictive power of the ConvNets is not a 
consequence of spurious correlations.  
We previously showed that data augmentation represents a versatile approach to increase the 
predictive power of Random Forest models trained on compound fingerprints[82]. Similarly, we 
here find a significant increase in performance for ConvNets trained on augmented data sets (P 
= 0.02). In fact, the utilization of data augmentation during training led to the most predictive 
models in 68% of the cases; when considering the most predictive network for each data set 
and run only, we find that data augmentation was used in 91% of the cases. Overall, these 
results indicate that the extraction of chemical information by the ConvNets is robust against 
rotations of the compound images, and that data augmentation helps improve chemical-
structure activity modelling based on compound images[82]. 
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Next, we compared the predictive power of the ConvNets to that of RF and DNN models trained 
on Morgan fingerprints of increasingly higher dimensionality (from 128 to 2048 bits) using the 
factorial design described in Equation 2. The linear model in this case showed an adjusted R2 
value of 0.97, suggesting that the covariates we considered account for most of the variability in 
model performance. Overall, we did not find significant differences in performance between RF 
models, DNN trained on circular fingerprints and ConvNets trained on compound images (P = 
0.76; Figures 4-5). The former models are using Morgan FP and RF or DNN, which have 
previously been shown to generate models with high predictive power in benchmarking studies 
of compound descriptors and algorithms[82–84]. Taken together, these results suggest that 
compound images provide sufficient predictive signal to generate ConvNets with comparable 
predictive power to state-of-the-art methods, even for small data sets of few hundred 
compounds. 
As an additional validation of our modelling framework, we extended our analysis to 25 protein 
target data sets (Table 2). We trained ConvNets using the ResNet-152 and VGG-19-bn 
architectures given their higher performance when modelling the cytotoxicity data sets 
described above. Overall, we obtained comparable performance for ConvNets, RF and DDN 
models (Figure 6), with effect sizes across algorithms in the 0.03-0.09 RMSE (i.e., pIC50) units 
range. Y-scrambling experiments for these data sets also led to R2 values around 0 (P < 0.001). 
We next capitalized on the large number of compounds annotated with bioactivity data for both 
COX-1 and COX-2[85, 86] to model COX isoform selectivity using multi-task ConvNets trained 
on compound images. Multi-task ConvNets displayed comparable performance to single-task 
ConvNets trained using either COX-1 or COX-2 data, with RMSE on the test set in the 0.72-0.75 
range, which are comparable to the uncertainty in heterogeneous pIC50 data extracted from 
ChEMBL[87]. Together, these results indicate that ConvNets extract structural aspects related 
to compound activity from compound images, which in turn enable the modelling of diverse 
bioactivity read-outs (compound potency and cell growth inhibition), measured in target systems 
of increasing complexity, from purified proteins to cell cultures. 
Table 4 Predictive power on the test set of multi-task and single-task 
models trained on the COX-1 and COX-2 data sets. 
Model RMSE +/- std on COX-1 RMSE +/- std on COX-2 
Multi-target COX-1 & COX-2 0.73 +/- 0.05 0.75 +/- 0.05 
Single-target COX-1 0.73 +/- 0.06 NA 
Single-target COX-2 NA 0.72 +/- 0.05 
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To further characterize the differences between RF and ConvNets, we firstly assessed the 
correlation between the predicted values calculated for the same test set instances using 
models trained on the same data splits. We found (as shown in Figure 7) that the predictions of 
both models are highly correlated for all data sets, with R2 values in the 0.80-0.89 range 
(Pearson’s correlation coefficient; P < 0.05), thus indicating that the predictions calculated with 
the RF models explain a large fraction of the variance observed for the predictions calculated 
with the ConvNets, and vice versa. Analysis of the correlation of the absolute error in prediction 
for each test set instance however revealed that the error profiles of RF and ConvNets are only 
moderately correlated (R2 in the 0.58-0.65 range, P < 0.05; Figure 8). From the latter, we 
hypothesized that combining the predictions generated by each modelling technique into a 
model ensemble might lead to increased predictive power[85]. In fact, ensemble models built by 
averaging the predictions generated by RF and ConvNet models displayed higher predictive 
power in some cases, leading to 4-12% and 5-8% decrease in RMSE values with respect to RF 
and ConvNet models, respectively (P < 10-5; pink bars in Figures 4 and 6). In contrast to 
previous analyses[51], where compound fingerprints and related representations were often 
thought to contain most information related to bioactivity[88], our results indicate that Morgan 
fingerprints and the features extracted from compound images with the ConvNets convey 
complementary predictive signal for some data sets, thus permitting to obtain more accurate 
predictions than either model alone by combining them into a model ensemble.  
In this work, we show using 33 diverse data sets extracted from ChEMBL database that a 
proper design and parametrization of ConvNets is sufficient to generate highly predictive models 
trained on images of structural compound representations sketched using standard 
functionalities of commonly used software packages (e.g., RDkit). Therefore, exploiting such 
networks, which were designed for general image recognition tasks, and pre-trained on 
unrelated image data sets, represents a versatile approach to model compound activity directly 
from Kekulé structure representations in a purely data-driven fashion. However, it is paramount 
to note that the computational footprint of ConvNets still represents a major limitation of this 
approach: whereas training the Random Forest models for these data sets required 6-14 
seconds per model using 16 CPU cores and no parameter optimization, training times per 
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epoch for the ConvNets were in the 15-64 seconds range (i.e., 150-640 minutes per model 
using one GPU card and 16 CPU cores for image processing). 
While the computation of compound descriptors has traditionally relied on predefined rules or 
prior knowledge of chemical properties, bioactivity profiles or topological information of 
compounds, among others[89–92], the descriptors calculated by the convolutional layers of 
ConvNets represent an automatic and data-driven approach to derive features directly from 
chemical structure representations[42], as we do here, or from image representations of a 
predefined set of molecular and topological features[41, 42]. As we show in this study, these 
compound features permit to model compound bioactivity with high accuracy even on a 
continuous scale. However, image-derived features are generally harder to interpret than more 
traditional descriptors, e.g., keyed Morgan fingerprints[85], although few methods to interpret 
convolutional graphs have been previously proposed[41, 93]. We anticipate that extending the 
work presented here by including 3D representations of compounds and binding sites using 3D 
convolutional neural networks to account for conformational changes of small molecules and 
protein dynamics, respectively, will likely improve compound activity modelling[94–98].  
 
Previous work using compound images and neural networks to model compound toxicity has 
shown that using a molecular representation where atoms are colored yields high predictive 
power[23]. We note that there are countless sketching protocols to represent molecules, and 
hence, future benchmarking studies will be needed to thoroughly examine their predictive 
signal. Similarly, elucidating the most convenient strategies to perform data augmentation is an 
area of intense research[99–101], also for chemical structure-activity modelling[82, 102]. In the 
case of ConvNets, multiple representations of the same molecules generated using diverse 
sketching schemes (e.g., using diverse SMILES encoding rules[102]) might be implemented to 
perform data augmentation. Future comparative studies of data augmentation strategies will 
also be needed to determine the most appropriate one for bioactivity modelling using ConvNets.  
 
The neural network architectures used in this study require the input images to be of size 
224x224, as modelling larger images would result in a computationally intractable increase in 
the number of parameters. Therefore, we generated images of that size for all compounds. 
Such an approach however results in larger representations for small molecules as compared to 
larger ones. Therefore, the same chemical moiety might span a larger or smaller region in the 
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images depending on the size of the molecule in which it appears. To account for this issue, 
images could be cropped to enlarge functional groups as a data augmentation strategy during 
the learning process. In this study, we did not investigate this data augmentation strategy further 
as the generalization capability of the networks we generated was comparable to that of RF and 
fully-connected networks trained on Morgan fingerprints. Thus, the influence on model 
performance of the relative size of the representations of chemical moieties and functional 
groups across molecules remains to be thoroughly examined. 
 
Finally, future work will also be required to evaluate whether ConvNets trained on both 
compound and cellular images lead to more accurate modelling of compound activity on cancer 
cell lines, as well as other output variables (i.e., toxicity), than current modelling approaches 
based on gene expression or mutation profiles[15, 16, 18, 103]. 
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Conclusions 
In this contribution, we introduce KekuleScope, a framework to model compound bioactivity on a 
continuous scale using extended versions of four widely-used architectures trained on Kekulé 
structure representations without requiring any image preprocessing or network engineering 
steps. The generated models achieve comparable performance to RF and DNN models trained 
on circular fingerprints, and to the estimated experimental uncertainty of the input data. Our 
work shows that Kekulé representations can be harnessed to derive robust models without 
requiring any additional descriptor calculation. In addition, we show that the chemical 
information extracted by the convolutional layers of the ConvNets is often complementary to that 
provided by Morgan fingerprints, which enables the generation of model ensembles with 
significantly higher predictive power than either RF models or ConvNets alone, although the 
effect size is small. The framework proposed here is generally applicable across endpoints, and 
it is expected that also on other datasets the combination of models will lead to increases in 
performance. 
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Figures 
 
Figure 1 KekuleScope framework. (A) We collected and curated a total of 8 cytotoxicity data 
sets from ChEMBL version 23. (B) Compound Kekulé representations were generated for all 
compounds and used as input to the ConvNets. (C) We implemented extended versions of 4 
commonly used architectures (e.g., VGG-19-bn shown in the Figure) by including five additional 
fully-connected layers to predict pIC50 values on a continuous scale. (D) The generalization 
power of the ConvNets was assessed on the test set, and compared to Random Forest models 
trained using Morgan fingerprints as covariates.  
Figure 2  Benchmarking the predictive power of ConvNet architectures on cytotoxicity 
data sets. Mean RMSE values (+/- standard deviation) on the test set across ten runs for each 
of the ConvNet architectures explored in this study (AlexNet[57], DenseNet-201[58], 
ResNet152[59] and VGG-19[60]). Overall, all architectures enabled the generation of models 
with high predictive power on the test set, with RMSE values in the 0.65-0.96 pIC50 range. 
However, the extended versions of these architectures that we designed by including 5 fully-
connected layers (see Figure 1) constantly led to increased predictive power on the test set. 
Figure 3 Analysis of the residuals. Residuals for the ConvNets (top panels) and RF (bottom 
panels) models for the cytotoxicity data sets. Overall, the residuals for both types of models 
show comparable variance across the bioactivity range (A) and are centered around zero (B), 
indicating that compound images permit to model the activity of small molecules across a 
dynamic range of pIC50 values.  
Figure 4 Comparing the predictive power of ConvNets, DNN and RF models using 8 
cytotoxicity data sets. Mean RMSE values (+/- standard deviation) on the test set across ten 
runs for (i) the ConvNet showing the highest predictive power for each data set and run 
combination, (ii) RF models trained on Morgan fingerprints, (iii) DNN trained on Morgan 
fingerprints, and (iv) the ensemble models built by averaging the predictions generated with the 
RF models trained on Morgan fingerprints of 2048 bits and ConvNet models trained on 
compound images. The yellow bars correspond to the RMSE values that would be obtained by 
a model predicting the average bioactivity value in the training data for all the test set instances. 
Overall, it can be seen that ConvNets lead to comparable predictive power than RF and DNN 
models (the effect size is small and not significant, ANOVA test). On average, ensemble models 
displayed higher predictive power than either model alone (Equation 2; P < 10-5), leading to 4-
12% and 5-8% decrease in RMSE values with respect to RF and ConvNet models. However, 
the effect size is small in all cases. 
Figure 5 Predictions for the test set molecules. Observed against predicted pCI50 values for 
the test set compounds calculated using ConvNets (top panels) or RF models (bottom panels). 
The results for the ten repetitions are shown (in each repetition the molecules in the training, 
validation and test sets were different). Overall, both RF models and ConvNets generated 
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comparable error profiles across the entire bioactivity range considered, showing Pearson's 
correlation coefficient values in the 0.72-0.84 range. 
Figure 6 Benchmarking the predictive power of ConvNets, DNN and RF models on 25 
protein target data sets. Mean RMSE values (+/- standard deviation) on the test set across ten 
runs for (i) the ConvNet showing the highest predictive power for each data set and run 
combination, (ii) RF models trained on Morgan fingerprints, (iii) DNN trained on Morgan 
fingerprints, and (iv) the ensemble models built by averaging the predictions generated with the 
RF models trained on Morgan fingerprints of 2048 bits and ConvNet models trained on 
compound images. As in Figure 4, the yellow bars correspond to the RMSE values that would 
be obtained by a model predicting the average bioactivity value in the training data for all the 
test set instances. Similar to the results obtained for the cytotoxicity data sets, we obtained 
ConvNets with comparable predictive power to RF and DNN models. As in the case of the 
cytotoxicity data sets, ensemble models often displayed higher predictive power than either 
model alone (Equation 2; P < 10-5).  
Figure 7 RF and ConvNet predictions on the test set. Correlation between the predictions for 
the test set compounds calculated with RF models and ConvNets trained on the same training 
set instances. Overall, the predictions show a positive and significant correlation (P < 0.05; 
Pearson's correlation coefficient values in the 0.72-0.84 range). The predictions for the ten runs 
are shown. 
Figure 8 Absolute errors in prediction. Relationship between the absolute errors in prediction 
for the same test set instances calculated with ConvNets (x-axis) and RF (y-axis) models 
trained on the same training set instances. The predictions generated by each model differ in >2 
pIC50 units in some cases, and are moderately correlated (R2 in the 0.58-0.65 range; P < 0.05). 
Note that most of the instances are located in the lower-left quadrant (bins coloured in blue), 
thus indicating that the absolute errors in prediction for most instances (i.e., those instances in 
the diagonal in the plots shown in Figure 7) are low and correlated for the two modelling 
strategies. This is expected given the high predictive power of the models (Figure 4) and the 
correlation of the predictions (Figure 7).  
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